| 216168 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
A Phase I study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) in combination with tremelimumab in patients with advanced solid tumors |
2015-11-04 |
10.1186/2051-1426-3-s2-p165 |
Papadopoulos Kyriakos P, Tsai Frank, Hamid Omid, Xiao Feng, Steele Keith E, Rebelatto Marlon C, Robbins Paul B, Karakunnel Joyson J, Lai Dominic W, Mahipal Amit |
| 216167 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Precision immunophenotyping by high-throughput TCR sequencing in human glioma |
2015-11-04 |
10.1186/2051-1426-3-s2-p387 |
Sims Jennifer, Grinshpun Boris, Feng Yaping, Ung Timothy, Neira Justin, Samanamud Jorge, Canoll Peter, Shen Yufeng, Sims Peter, Bruce Jeffrey |
| 216166 |
SENSORS |
A New Analytic Alignment Method for a SINS |
2015-11-04 |
10.3390/s151127930 |
Tan Caiming, Zhu Xinhua, Su Yan, Wang Yu, Wu Zhiqiang, Gu Dongbing |
| 216165 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Immune correlates in a Phase II clinical trial with ipilimumab in combination with finite androgen deprivation therapy in patients with metastatic non-castrate prostate cancer |
2015-11-04 |
10.1186/2051-1426-3-s2-p106 |
Subudhi Sumit K, Aparicio Ana, Gao Jianjun, Zurita Amado, John Araujo, Logothetis Christopher, Rao Brinda, Vence Luis, Allison James, Emerson Ryan O, Yusko Erik, Vignali Marissa, Robins Harlan, Sun Jing Jing, Sharma Padmanee |
| 216164 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Tumor kinetics prior to treatment correlate with response to checkpoint inhibitors |
2015-11-04 |
10.1186/2051-1426-3-s2-p252 |
Cadena Alexandra P, Welsh James, Tang Chad, Raju Uma, Hong David, Naing Aung, Godoy Myrna, Allen Pamela K, Schoenhals Jonathan, Cortez Maria Angelica |
| 216163 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
CD47-blocking therapies stimulate macrophage cytokine secretion and are effective in a model of peritoneal carcinomatosis |
2015-11-04 |
10.1186/2051-1426-3-s2-p248 |
Weiskopf Kipp, Ring Aaron, Garcia K Christopher, Weissman Irving |
| 216162 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer |
2015-11-04 |
10.1186/2051-1426-3-s2-p147 |
Cohen Ezra EW, Moore Kathleen N, Slomovitz Brian M, Chung Christine H, Anderson Matthew L, Morris Shannon R, Mauro David, Burtness Barbara |
| 216161 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Pilot clinical trials testing the safety and effects on the metastatic melanoma microenvironment of intratumoral interferon-gamma or imiquimod, plus a multipeptide melanoma vaccine |
2015-11-04 |
10.1186/2051-1426-3-s2-p139 |
Mauldin Ileana S, Wages Nolan A, Stowman Anne M, Wang Ena, Smolkin Mark E, Olson Walter C, Deacon Donna H, Smith Kelly T, Galeassi Nadejda, Teague Jessica E, Clark Rachael A, Marincola Francesco M, Petroni Gina R, Mullins David W, Slingluff Craig L |
| 216160 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Il-6 is non-essential to murine CD19 CAR efficacy, but can mediate acute GVHD following allogeneic BMT with CAR T cell infusion |
2015-11-04 |
10.1186/2051-1426-3-s2-p226 |
Jacoby Elad, Qin Haiying, Kochenderfer James, Yang Yinmeng, Chien Chris, Fry Terry |
| 216159 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Clinical significance of PD-L1 protein expression on tumor-associated macrophages in lung cancer |
2015-11-04 |
10.1186/2051-1426-3-s2-p415 |
Schalper Kurt Alex, Carvajal-Hausdorf Daniel, McLaughlin Joseph, Velcheti Vamsidhar, Chen Lieping, Sanmamed Miguel, Herbst Roy S, Rimm David L |
